2. Signaling Pathways
  3. Immunology/Inflammation
  4. Nectin-4

Nectin-4

 
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99016
    Enfortumab
    		Inhibitor 99.90%
    Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma.
    Enfortumab
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)
    		Inhibitor 99.78%
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma.
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv
    		Inhibitor 99.28%
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma.
    Enfortumab vedotin-ejfv
  • HY-P10524A
    N188 TFA
    		99.74%
    N188 TFA is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 TFA can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 TFA and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma.
    N188 TFA
  • HY-P10524
    N188
    N188 is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma.
    N188
Cat. No. Product Name / Synonyms Application Reactivity